Clinical trial · Interventional
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors
NCT01980667CI-TRIAL-00025643completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| lurbinectedin (PM01183) | Drug | Lurbinectedin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- lurbinectedin (PM01183) / cisplatin
- description
- Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
- interventionNames
- Drug: lurbinectedin (PM01183)
- Drug: Cisplatin
Primary outcomes (1)
- measure
- Recommended dose (RD) of the combination PM01183 and cisplatin
- timeFrame
- 30 months
- description
- To determine the recommended dose (RD) of PM01183 in combination with cisplatin every three weeks (q3wk) with or without aprepitant in patients with advanced solid tumors. The RD will be the dose level (DL) immediately below the maximum tolerated dose (MTD), that is, the highest DL explored at which less than one third of evaluable patients experience a DLT during Cycle 1.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntarily signed written informed consent * Age ≥ 18 years old * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1. * Life expectancy ≥ 3 months. * Patients with confirmed diagnosis of advanced solid tumors. * Patients may have received ≤ 2 chemotherapy-containing lines in the advanced setting. * Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ seven days before inclusion in the study) * Recovery or stabilization to grade ≤ 1 from any adverse event derived from previous treatment (up to grade 2 alopecia or asthenia/fatigue are allowed). * No clinically significant changes in ECG. * At least four weeks since the last monoclonal antibody containing therapy or definitive radiotherapy (RT) * At least two weeks since the last biological/investigational single-agent therapy (excluding MAbs) and/or palliative RT (≤10 fractions or ≤30 Gy total dose) * Fertil women must have pregnancy excluded by appropriate testing before study entry Exclusion Criteria: * Prior treatment with PM01183 or trabectedin. * Concomitant diseases/conditions: * History within the last year or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically relevant valvular heart disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia requiring ongoing treatment. * Ongoing, non-neoplastic, chronically active liver disease of any origin. * Active infection. * Patients who are requiring any ongoing oxygen support. * Known human immunodeficiency virus (HIV) infection. * Any other major illness. * Symptomatic or corticosteroid-requiring brain metastases or leptomeningeal disease involvement. Patients with asymptomatic documented stable brain metastases not requiring corticosteroids during the last three months are allowed. * Peripheral sensory/motor neuropathy grade \>1. Hearing impairment grade \>1. * Fertile men or women not using an effective method of contraception. * History of bone marrow or stem cell transplantation * Radiotherapye to \>35% of the bone marrow.
References
Publications (1)
- DERIVEDMetaxas Y, Kahatt C, Alfaro V, Fudio S, Zeaiter A, Plummer R, Sessa C, Von Moos R, Forster M, Stathis A. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors. Invest New Drugs. 2022 Feb;40(1):91-98. doi: 10.1007/s10637-021-01142-1. Epub 2021 Aug 28. PMID 34453241